Frontlight ResearchEarly access
CompletedNo phase
Cellular Reprogramming-Enhanced Skin Grafting for Diabetic Foot Ulcers
Key facts
- Who runs it
- Hu Zhicheng
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 108 people enrolled
- Started
- 1 Aug 2017
- Ended
- 30 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- autologous skin cell
- skin graft
- Record updated
- 18 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- .Adults aged ≥18 years with type 1 or type 2 diabetes mellitus, diagnosed according to WHO criteria
- .Presence of a chronic diabetic foot ulcer located below the ankle, classified as Wagner grade 2-3, with a post-debridement area of 5-80 cm²
- .Target ulcer present for ≥4 weeks and unhealed despite ≥4 weeks of standard wound care prior to randomization
- .HbA1c <12%, measured at screening or within 3 months prior to randomization
- .Any revascularization of the affected limb completed ≥4 weeks before randomization
- .Ability to provide written informed consent and comply with all study procedures and follow-up requirements
Who cannot take part
- .Revascularization of the affected limb planned or performed within 4 weeks prior to randomization
- .Participation in another interventional clinical trial within 3 months prior to randomization
- .Active infection of the target ulcer requiring systemic antibiotics, or presence of non-removable necrosis, purulence, or sinus tracts
- .Significant peripheral arterial disease, defined as ABI <0.7 or >1.3
- .Active malignancy, uncontrolled autoimmune disease, or current use of systemic immunosuppressive therapy
- .Hematologic disorders that may impair wound healing
- .HIV infection or active hepatitis
- .Any condition that, in the investigator's judgment, could impair informed consent, protocol compliance, patient safety, or data reliability
- .End-stage renal disease or eGFR <20 mL/min/1.73 m²
- .Pregnancy, lactation, or intention to become pregnant during the study period
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Diabetic foot ulcer is one of the refractory wounds and always poses many challenges in clinical practice. This study was conducted to have a prospective, randomised, controlled study compare the safety and efficacy of the autologous skin cell with skin graft (experiment group) with split-thickness skin graft (STSG, control group) alone on treating diabetic foot ulcers.
The 2 groups in the trial
- autologous skin cellTreatment being tested
autologous skin cell with skin graft
- skin graftExisting treatment, for comparison
split-thickness skin graft as control group
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intraoperative Cellular Reprogramming-Enhanced Skin Transplantation for Diabetic Foot Ulcers: A Randomized Clinical Trial
- Record updated
- 18 February 2026